The Substance Abuse and Mental Health Services Administration (SAMHSA) expanded its list of prohibited harm reduction services to exclude drug testing strips in new guidance documents. The updated guidance prohibits test kits that can be used to test for the presence of fentanyl or xylazine in drugs, which were explicitly allowed in a July letter. The new guidance also clarifies that federal funding can’t be used to operate overdose hotlines whose primary purpose is “facilitating illicit drugs use by providing people using drugs a virtual or telephonic companion while they are using drugs.”